₩8,420.00 ($6.27)

-40.00 (-0.47%)

Weekly Expected Move ±5.5%

₩7500 ₩7960 ₩8420 ₩8880 ₩9340

KSC · Healthcare · Medical - Pharmaceuticals · Tech Score Sell · Power 33 · ₩711.3B mcap · 28M float · 0.425% daily turnover

Revenue

$1.02T +0.0% ▲

5Y CAGR: +12.6%

Gross Profit

$352.5B -3.0% ▼

5Y CAGR: +8.8%

Operating Income

$65.1B -7.7% ▼

5Y CAGR: +10.2%

Net Income

$80.9B +16.2% ▲

5Y CAGR: +24.7%

EPS (Diluted)

$957.44 -5.8% ▼

5Y CAGR: +16.2%

EBITDA

$108.6B -5.4% ▼

5Y CAGR: +10.2%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$627.3B	$760.5B	$859.6B	$1.02T	$1.02T
YoY Growth	+11.6%	+21.2%	+13.0%	+18.3%	+0.0%
Cost of Revenue	$362.3B	$453.3B	$506.2B	$653.7B	$664.9B
Gross Profit	$264.9B	$307.2B	$353.4B	$363.4B	$352.5B
Gross Margin	42.2%	40.4%	41.1%	35.7%	34.6%
R&D Expenses	$39.1B	$41.7B	$47.3B	$51.5B	$0
SG&A Expenses	$89.5B	$92.0B	$92.1B	$99.1B	$0
Operating Expenses	$211.0B	$250.6B	$285.2B	$292.9B	$287.4B
Operating Income	$41.4B	$56.6B	$68.3B	$70.5B	$65.1B
Operating Margin	6.6%	7.4%	7.9%	6.9%	6.4%
Interest Expense	$4.5B	$6.1B	$9.5B	$9.0B	$11.6B
Income Before Tax	$70.7B	$58.9B	$56.3B	$63.0B	$69.8B
Tax Expense	$27.6B	$16.9B	$16.1B	-$6.7B	$5.5B
Net Income	$43.0B	$41.9B	$40.2B	$69.6B	$80.9B
Net Margin	6.9%	5.5%	4.7%	6.8%	7.9%
EPS (Diluted)	$682.93	$633.55	$609.77	$1016.00	$957.44
EBITDA	$81.8B	$105.7B	$110.2B	$114.8B	$108.6B
Shares Outstanding	63M	66M	66M	69M	84M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$271.0B	$256.9B	$240.6B	$251.5B	$280.0B	$245.3B	$255.4B	$279.6B
Cost of Revenue	$179.8B	$168.5B	$153.8B	$154.2B	$176.7B	$165.4B	$165.7B	$182.3B
Gross Profit	$91.2B	$88.5B	$81.9B	$97.3B	$98.3B	$80.0B	$89.7B	$97.3B
Gross Margin	33.7%	34.4%	34.0%	38.7%	35.1%	32.6%	35.1%	34.8%
R&D Expenses	$0	$14.0B	$16.1B	$14.1B	$15.6B	$19.3B	$12.8B	$0
SG&A Expenses	$71.8B	$22.5B	$27.5B	$72.0B	$22.6B	$24.0B	$25.9B	$57.3B
Operating Expenses	$71.8B	$73.9B	$69.9B	$72.0B	$68.9B	$80.6B	$69.5B	$73.5B
Operating Income	$19.5B	$14.5B	$10.9B	$25.4B	$29.4B	-$649M	$20.2B	$23.8B
Operating Margin	7.2%	5.7%	4.5%	10.1%	10.5%	-0.3%	7.9%	8.5%
Interest Expense	$2.2B	$2.2B	$1.8B	$2.6B	$3.0B	$4.1B	$3.0B	$3.1B
Income Before Tax	$10.6B	$14.6B	-$2.9B	$10.6B	$43.5B	$18.7B	$53.9B	$31.6B
Tax Expense	$1.3B	$1.3B	-$3.3B	$1.8B	$9.5B	-$2.4B	$12.5B	$7.6B
Net Income	$9.4B	$13.2B	$349M	$8.9B	$34.0B	$21.1B	$41.4B	$24.1B
Net Margin	3.5%	5.2%	0.1%	3.5%	12.1%	8.6%	16.2%	8.6%
EPS (Diluted)	$142.00	$162.38	$5.09	$106.00	$405.00	$249.65	$493.00	$287.00
EBITDA	$19.5B	$27.5B	$9.6B	$35.8B	$57.8B	$10.6B	$31.3B	$37.5B
Shares Outstanding	66M	82M	69M	69M	84M	84M	86M	86M

003850.KS KSC